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Abstract
Background: Patients with rheumatoid arthritis have a higher risk of low bone mineral density
than normal age matched populations. There is limited evidence to support cost effectiveness of
population screening in rheumatoid arthritis and case finding strategies have been proposed as a
means to increase cost effectiveness of diagnostic screening for osteoporosis. This study aimed to
assess the performance attributes of generic and rheumatoid arthritis specific clinical decision tools
for diagnosing osteoporosis in a postmenopausal population with rheumatoid arthritis who attend
ambulatory specialist rheumatology clinics.
Methods: A cross-sectional study of 127 ambulatory post-menopausal women with rheumatoid
arthritis was performed. Patients currently receiving or who had previously received bone active
therapy were excluded. Eligible women underwent clinical assessment and dual-energy-xray
absorptiometry (DXA) bone mineral density assessment.
Clinical decision tools, including those specific for rheumatoid arthritis, were compared to seven
generic post-menopausal tools to predict osteoporosis (defined as T score < -2.5). Sensitivity,
specificity, positive predictive and negative predictive values and area under the curve were
assessed. The diagnostic attributes of the clinical decision tools were compared by examination of
the area under the receiver-operator-curve.
Results: One hundred and twenty seven women participated. The median age was 62 (IQR 56–71)
years. Median disease duration was 108 (60–168) months. Seventy two (57%) women had no
record of a previous DXA examination. Eighty (63%) women had T scores at femoral neck or
lumbar spine less than -1. The area under the ROC curve for clinical decision tool prediction of T
score <-2.5 varied between 0.63 and 0.76. The rheumatoid arthritis specific decision tools did not
perform better than generic tools, however, the National Osteoporosis Foundation score could
potentially reduce the number of unnecessary DXA tests by approximately 45% in this population.
Conclusion: There was limited utility of clinical decision tools for predicting osteoporosis in this
patient population. Fracture prediction tools that include risk factors independent of BMD are
needed.
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Background
Worldwide, the burden of osteoporotic fractures accounts
for 0.83% of the global burden of non communicable dis-
ease [1] that can be measured in any community by asso-
ciated morbidity, mortality and cost to the community
[2]. Cost effective interventions are recommended for
those with prevalent fragility fractures, however the role of
diagnostic screening and intervention for those with low
bone density and osteoporosis but no history of fracture
is less well established. Low bone mass, most commonly
measured using dual-energy xray absorptiometry (DXA)
assessment of bone mineral density (BMD) is the most
important risk factor for fracture [3] however other risk
factors independent of BMD need to be considered and a
number of these risk factors have been incorporated into
targeted case finding clinical decision tools in attempts to
improve the cost effectiveness of screening and potentially
reduce the numbers of people undergoing unnecessary
DXA tests [4-8]. The development of multiple tools may
reflect disappointing performance of these tools when
applied to populations other than the one within which
they were developed [5].
Rheumatoid arthritis (RA) is an inflammatory arthritis
that has been shown to be associated with low BMD, and
a higher risk of fragility fracture [9,10]. Current guidelines
advocate a case-finding approach to screening [11], with
secondary causes such as rheumatoid arthritis being an
indication. In Australia, diagnostic screening for oste-
oporosis in people with rheumatoid arthritis is subsidised
by the National Health Scheme (Medicare) however a pre-
vious audit of assessment of osteoporosis risk by rheuma-
tologists suggested use of DXA screening was limited to a
subset of rheumatoid arthritis patients, primarily women
who were on glucocorticosteroid treatment [12]. Whilst
there is some evidence to support cost-effectiveness of
screening and treating post menopausal women with
rheumatoid arthritis who are starting corticosteroid treat-
ment [13], the cost effectiveness of screening an unse-
lected post-menopausal rheumatoid arthritis population
has not been reported. Clinical criteria for case targeted
BMD screening for rheumatoid arthritis patients are avail-
able [14] however their performance attributes have also
varied across rheumatoid arthritis populations and it is
uncertain whether they offer significant advantage over
existing generic models for post-menopausal populations
[15].
This study aimed to test the performance of generic and
rheumatoid arthritis specific case finding clinical decision
tools in a post-menopausal group of women with rheu-
matoid arthritis.
Methods
A cross-sectional study of post menopausal women with
rheumatoid arthritis was approved by the Alfred Hospital
and Cabrini Medical Centre Human Research Ethics Com-
mittees. All women gave informed consent for participa-
tion.
Inclusion criteria for participation included: age over 45
years, postmenopausal status defined by the absence of
menstrual periods for at least 12 months, a diagnosis of
rheumatoid arthritis defined by 1987 American Rheuma-
tology Association (ARA) criteria [16]. Exclusion criteria
included: current or previous treatment with bone active
agents other than hormone replacement therapy, calcium
or vitamin D, history of malignancy, renal impairment
where the serum creatinine was more than 0.2 mmol/l,
and unable or unwilling to give informed consent. In Aus-
tralia patients can choose to have specialist treatment in
public (entirely government funded) or private (govern-
ment subsidised) care settings. The 5 recruitment settings
included two university affiliated metropolitan public
hospital ambulatory care general rheumatology clinics
and three specialist rheumatology private practices. Study
participants were recruited in a consecutive fashion using
manual medical record screening.
Disease assessment was performed by a trained metrolo-
gist. Markers of disease activity included: duration of
morning stiffness (minutes), 68 swollen joint count, cur-
rent erythrocyte sedimentation rate (ESR, mm/hr). A com-
posite disease activity score, the DAS28T+S score [17] was
calculated. Markers of disease severity included: disease
duration (defined from the time of physician diagnosis),
presence of rheumatoid factor, radiological appearance of
typical rheumatoid arthritis erosions, numbers of disease
modifying anti-rheumatic drugs (DMARDs), number of
joint arthroplasty procedures, and presence of extra-artic-
ular features (nodules/vasculitis). Functional status was
assessed using the Modified Health Assessment Question-
naire (MHAQ) [18] and the American College of Rheuma-
tology global functional status [19]. A patient self-rated
global health score was also collected (excellent, good,
fair, poor). Prednisolone use was defined as 'current use'
or 'ever used'. Grip strength was measured using a cali-
brated instrument and the average of three measurements
on the dominant and non-dominant side were recorded.
The following osteoporotic risk factors were assessed: age
(years), body mass index (BMI) <20 kg/m2 [weight in kil-
ogram/(height in metres)2], current smoker, alcohol >3
standard glasses per day, caffeine >3 standard glasses per
day, sunlight exposure < 20 minutes three times per week,
calcium intake (<1000 mg/day, <250 mg/day), previous
history of low trauma fracture.BMC Musculoskeletal Disorders 2008, 9:13 http://www.biomedcentral.com/1471-2474/9/13
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Bone mineral density was assessed by DXA (Lunar or
Hologic devices) at a geographical location defined by
patient or clinician preference. This was designed to reflect
normal clinical management. Osteopenia was defined as
a T-score less than -1, and osteoporosis as a T-score less
than or equal to -2.5 at the femoral neck [20]. There is no
standardised quality assurance protocol, nor consistent
use of a normative reference dataset between DXA
machines which may lead to inter-site measurement error,
especially when comparing mean BMD levels. For this rea-
son, analysis of clinical decision tool performance was
based on prediction for T scores at the femoral neck only.
Clinical decision tools and Statistical analysis
The clinical decision tools are summarised in Table 1.
They were applied using methodology described within
original development and validation studies [5,6,15,21-
24] to assess their predictive value in identifying bone
mineral density scores of less than or equal to -2.5 at the
femoral neck. The sensitivity, specificity, positive predic-
tive and negative predictive values and area under the
curve were assessed as a measure of combined sensitivity/
specificity model behaviour [25]. The diagnostic
attributes of the clinical decision tools were compared by
examination of the area under the receiver-operator-curve
(ROC). The tool with the highest area under curve was
arbitrarily chosen as the comparison point using the "roc-
gold" command within Stata. (Stat 9.2, Copyright
1996–2007 StataCorp, College Station, TX 77845, USA).
Results
Two hundred and fifty five women were screened, repre-
senting 62.5% total potentially eligible rheumatoid
arthritis population. One hundred and thirty five women
did not respond to invitations to participate. One hun-
dred and twenty eight (50.2%) screened women were
excluded due to current or previous use of a bone active
medication (48, 37.5%), pre-menopausal status (47,
36.7%), medical co-morbidity (15, 11.7%) or refusal to
participate (6, 4.7%). One hundred and twenty seven
postmenopausal women consented to participate in the
study. Seventy-two (57%) had no record of a previous
Table 1: Summary of criteria described for clinical decision rules to predict low bone mineral density applied in a cohort of 127 post-
menopausal women with rheumatoid arthritis.
Guideline/Rule Selection Cut Point Scoring system
Simple Calculated Osteoporosis Risk 
Estimation (SCORE)(6)
Score ≥ 6 Points for: Race: 5 if not black
Rheumatoid arthritis: 4 if present
Personal history of minimal trauma fracture after age 45 yrs years: 4 each fracture 
of the wrist, hip, or rib to a maximum of 12
Age: 3 times first digit of age in yrs
Estrogen therapy: 1 if never used
Weight: -1 times weight in lb divided by 10 and truncated to integer
Osteoporosis Risk Assessment 
Instrument (ORAI)(4)
Score ≥ 9 Points for: Age: 15 if 75 yrs or older, 9 if 65–74 yrs, 5 if 55–64 yrs
Weight: 9 if <60 kg, 3 if 60.0–69.9 kg
Estrogen use: 2 if not currently taking estrogen
Age, Body Size, No Estrogen 
(ABONE)(23)
Score ≥ 2 Points for: Age: 1 if > 65 yrs
Weight: if <63.5 kg
Estrogen use: 1 if never used oral contraceptives or estrogen therapy for at least 
6 months
Body weight criterion(22) If Weight <70 kg
Osteoporosis Self Assessment Tool 
(OST)(8)
Score < 2 Sum of: (Weight – Age) * 0.2 truncated to an integer
Study of Osteoporotic Fractures 
(SOFSURF)(7)
Score ≥ 1 Sum of: (Age – 65) * 0.2
Plus 1 point each for
Weight less than 68 kg
Current smoker
Personal history of postmenopausal fracture
Plus 2 points if Weight < 59 kg.
National Osteoporosis Foundation 
(NOF)(21)
Score ≥ 1 One point each for: Age ≥ 65 yrs
Personal history of minimal trauma fracture >40 yrs
Family history of fracture
Current cigarette smoking
Amsterdam rheumatologists 
score(15)
Score ≥ 2 Points for: Disease activity (mean CPR > 20 mg/l or persistent ESR > 20 mm for 
the 1st hour
Age: women > 50 yrs
Immobility: ARA score = 3 or HAQ score ≥ 1.25.
Modified Amsterdam(24) Score ≥ 3 As per Amsterdam rheumatologist algorithm, with an additional point for each of
Weight: <60 kg
Any previous steroid useBMC Musculoskeletal Disorders 2008, 9:13 http://www.biomedcentral.com/1471-2474/9/13
Page 4 of 7
(page number not for citation purposes)
DXA assessment. Sixteen (12.6%) women had a history of
post-menopausal fracture.
The median age of participants was 62 yrs (interquartile
range {IQR} 56–71). The majority (124, 98%) were Cau-
casian. Disease duration was long [median 108 months
(IQR 60–168)]. Although only 10, (7.9%) reported a glo-
bal health score of fair or poor, 72 (57%) were ARA func-
tional status 111 and weakness to rise from a chair was
documented in 39 (30.7%). Other parameters including
arthroplasty (22, 17.3%), use of more than one disease
modifying anti-rheumatic drug (33, 25.9%) and current
use of prednisolone (44, 35%) are in keeping with a rheu-
matoid arthritis population of long disease duration. In
contrast, evidence of active joint disease was less impres-
sive with a low active joint count (median tender = 5, IQR
= 2–10, median swelling = 5, IQR = 2–9,), and short dura-
tion of early morning stiffness (median = 30 minutes 5,
IQR = 5–60 Patients with high disease activity (as meas-
ured by the DAS28T+S(17) had greater duration of early
morning stiffness (Spearman rho = 0.663, p < 0.001).
There was a high prevalence of low dietary calcium intake
(median 500 mg/day, IQR 250–825) and 15 (12%) had
less than 250 mg/day. 34 (27%) of women had 3 or more
risk factors for osteoporosis. Postmenopausal fragility
fractures were documented in 16 (13.0%) women, 43
(33.9%) recalled a fall within the twelve months prior to
assessment and for 17 (13.4%) this included two or more
falls. Fear of falling was reported as moderate or severe in
nearly one third of women.
The results of BMD are summarised in Table 2. Overall, 80
(64.5%) women had BMD T-scores less than -1, of whom
56 (45.2%) were less than -1 but greater than -2.5 and 24
(19.4%) were less than or equal to -2.5. There were no
clear differences in fracture and non fracture groups (fem-
oral neck mean t-score = -1.52, sd = 1.33 for fracture
group, compared with -1.09, sd = 1.38 for non fracture
group, p = 0.247, and lumbar spine mean t-score = -0.34
for fracture group compared with -1.09, sd = 1.38 for non-
fracture group, p = 0.870). The degree of current disease
activity (as measured by DAS28T+S) was not related to
bone mineral density (Spearman rho for t-score at femoral
neck = 0.049, p = 0.624, rho for t-score at lumber spine =
-0.098, p = 0.323).
The performance attributes of the scoring algorithms are
summarised in Table 3. None of the seven general scoring
algorithms that were tested performed significantly better
than the others as assessed by ROC curve analysis (range
0.63–0.76). The rheumatoid arthritis specific guideline
had the lowest area under the curve. When compared to
the OST, which had the highest area under ROC, the only
tool that performed substantially poorer was the "low
body weight" criterion (Bonferoni adjust p < 0.001).
Patients from public hospital rheumatology clinics had
more severe rheumatoid arthritis (poorer functional sta-
tus, longer early morning stiffness and higher swollen
joint count) and a higher ESR. Therefore, the diagnostic
models were applied with and without the public patients
included. The ROC values did not alter significantly there-
fore the reported values included all patients.
Discussion
Our findings of a high prevalence of risk factors for oste-
oporosis and low BMD among a postmenopausal popula-
tion of women with rheumatoid arthritis are in keeping
with previous studies. Rheumatoid arthritis has been
reported to be associated with localised [9] and general-
ised bone loss [26,27], increased risk of osteoporosis and
low trauma fractures [10,28]. Factors associated with low
bone density include disease activity, disability disease
duration as well as therapy with corticosteroids [29-31].
Further, in this study we have demonstrated the limited
utility of clinical decision tools, and lack of advantage of
Table 2: Results of bone mineral density measured by DXA postmenopausal women with Rheumatoid Arthritis (n = 127).
Site % T score > -1 T < -1 to -2.5 N (%) T < -2.5 N (%) Valid N
Total Group N = 127
Femoral Neck 87.2 52 (42.3) 18 (14.6) 123
Lumbar Spine 90.5 45 (31.7) 12 (9.8) 123
Non Fracture Group
Femoral Neck 88.2 40 (37.4) 14 (13.1) 107
Lumbar Spine 91.1 30 (28.0) 10 (9.3) 107
Fracture group
Femoral Neck 80.0 9 (56.3) 4 (25.0) 16
Lumbar Spine 86.7 6 (37.5) 2 (12.5) 16BMC Musculoskeletal Disorders 2008, 9:13 http://www.biomedcentral.com/1471-2474/9/13
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rheumatoid arthritis specific clinical decision tools for
predicting osteoporosis in this population. This is also in
keeping with previous studies of non selected post-meno-
pausal populations. Lydick et al [6] developed and vali-
dated a questionnaire, the Simple Calculated
Osteoporosis Risk Estimation ("SCORE") which included
6 variables (age, race, rheumatoid arthritis, non-traumatic
fracture >45 years, oestrogen use, weight) and reported
sensitivity of 89% and specificity of 50% for the tool.
However, when this "SCORE" was applied by Cadarette et
al [5] to a post-menopausal population in Toronto they
found it to have very poor specificity, with a high false
positive rate of 68%. More recently, application of three
clinical decision tools (SCORE, ORAI, NOF) to an inde-
pendent post menopausal population reported poor util-
ity as a general screening method [32]. If algorithms that
give a point estimate for sensitivity of at least 90% for pre-
diction of osteoporosis are considered, the algorithms
that approximate or exceed this criteria in our patient pop-
ulation without modification from the developers recom-
mendations, were the SCORE (100%) [6],
Amsterdam(100%) [15], NOF (94%) and SOF-
SURF(89%) [7]. However, the corresponding specificities
are 10% and 7% for SCORE and Amsterdam respectively,
suggesting it would be possible to exclude osteoporosis
without a DXA study in only approximately 10% of
patients who do not have the condition. The SOFSURF,
with a somewhat lower sensitivity, would reduce the
number unnecessary DXA studies by approximately 34%.
In our study population the best performing tool was the
NOF which, in addition to providing high sensitivity, has
the potential to reduce the number of unnecessary DXA
studies by approximately 45%.
Useful clinical decision tools need to be able to take
account of individual risk factor burden, including revers-
ible risk, and be easy to administer [33]. Poor predictive
performance of the clinical decision tools in our patient
population may be due to a number of factors. Firstly,
there is well known heterogeneity of osteoporosis risk in
different populations [34]. Secondly, heterogeneity
within the rheumatoid arthritis population may contrib-
ute to poor predictive utility. A single clinical decision
tool may not account for variability in osteoporosis risk
that is influenced by disease duration, activity and severity
[35]. Although we did not find differences in the perform-
ance of the clinical decision tools between public and pri-
vate patients in whom some differences in disease activity
and severity were noted, this study was not powered to
demonstrate such differences and larger studies are
required to assess this hypothesis. Overall, our data adds
support to a recent systematic review of the performance
of the Osteoporosis Self-Assessment Tool (OST) that sug-
gests clinical decision tools may be more useful in identi-
fying a subset of patients who are at low risk of
osteoporosis and do not need formal bone mineral den-
sity assessment [36].
The rationale for using clinical decision tools to predict
osteoporosis is that BMD is known to be a major risk fac-
tor for fracture and that there is a site specific gradient to
risk [33]. Unless there is consensus about the long-term
safety and effectiveness of fracture prevention therapy as
well as demonstrated high levels of compliance with pre-
ventive therapy, applying clinical decision tools that accu-
rately predict low risk of osteoporosis may support cost-
effective approaches to diagnosis and management. How-
ever, previous reports, supported by our data, indicate
that fracture can occur in the presence of normal BMD. In
addition, other factors, independent of BMD can be
important predictors of an individual's incident fracture
risk [33]. Whilst one of the major independent predictive
factors, age is not reversible, other factors including falls,
reduced mobility and use of corticosteroids all of which
are important to our patient population, may be amena-
ble to non pharmacological interventions. Therefore, clin-
ical indices for predicting fracture in addition to BMD
measurement would potentially provide greater utility for
clinical management [33]. The number of patients with
fracture was too small in our population to test decision
Table 3: Attributes of clinical decision tools for predicting T Score less than or equal to -2.5 (at the femoral neck) in 127 post-
menopausal women with rheumatoid arthritis
Predictive values
T-FN < -2.5 Sensitivity (95% CI) Specificity (95% CI) Positive (95% CI) Negative (95% CI) Area Under Curve (95% CI)
SCORE 100 (82–100) 10 (5–17) 16 (10–24) 100 (69–100) 0.73 (0.59–0.86)
ORAI 72 (47–90) 50 (40–60) 20 (11–31) 91 (81–97) 0.73 (0.59–0.87)
NOF 94 (73–100) 46 (36–56) 23 (14–34) 98 (89–100) 0.75 (0.65–0.85)
ABONE 56 (31–79) 84 (75–90) 37 (19–58) 92 (84–96) 0.72 (0.58–0.85)
OST 78 (52–94) 51 (41–61) 22 (12–34) 93 (83–98) 0.76 (0.64–0.89)
SOFSURF 89 (65–99) 34 (25–44) 19 (11–29) 95 (82–99) 0.72 (0.59–0.85)
Low Body Weight 72 (47–90) 53 (43–63) 21 (12–33) 92 (82–97) 0.63 (0.51–0.74)
Amsterdam 100 (82–100) 7 (3–14) 16 (10–24) 100 (59–100) 0.64 (0.51–0.76)
Modified Amsterdam 78 (52–94) 44 (34–54) 20 (11–31) 92 (80–98) 0.70 (0.57–0.83)BMC Musculoskeletal Disorders 2008, 9:13 http://www.biomedcentral.com/1471-2474/9/13
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tool predictive performance for fracture rather than oste-
oporosis, however other authors report limited utility of
clinical indices for prediction of fracture risk in postmen-
opausal populations [37]. This need to be further investi-
gated for patients with rheumatoid arthritis and other
high risk populations.
The study had further limitations. Bone densitometry was
performed using a variety of different DXA machines that
may have contributed to significant undetected technical
error in measurement [33]. However, the study was specif-
ically designed to provide a pragmatic clinical population
assessment and it is unlikely that this would have signifi-
cantly affected the results. Consecutive recruitment of
patients was undertaken to reduce selection bias, however
individual practitioner practice behaviours may have also
influenced the utility of clinical decision tools. The study
was not powered to assess this question. The study also
was restricted to a female post-menopausal population
and the results may not be generalisable to males with
rheumatoid arthritis. Generalisation to a wider commu-
nity rheumatoid arthritis population is limited as patients
with mild rheumatoid arthritis, not regularly attending a
rheumatologist, may have been excluded from assess-
ment. Inclusion of such patients however would be more
likely to reduce the utility of the tools.
Even excluding patients in whom there was current or pre-
vious treatment with bone active agents other than HRT,
calcium or vitamin D, there were over 10% with a history
of fracture since the age of 50 years. As the study did not
include assessment of appropriateness of care, nor vali-
date self reported information with general practice
records and radiographs, it is not possible to draw conclu-
sions from this data.
Conclusion
In summary, rheumatoid arthritis specific clinical deci-
sion tools for identifying postmenopausal women with
RA who have low bone mineral density and osteoporosis
demonstrated no greater performance than clinical deci-
sion tools developed for use in non selected postmeno-
pausal populations. A trade-off between clinical decision
tools' high sensitivity performance and avoidance of
unnecessary DXD scanning needs to be further investi-
gated in a larger RA population study where the influence
of clinician osteoporosis management, heterogeneity of
RA disease factors and independent risk factors for frac-
ture can be assessed.
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